Midatech Pharma PLC (MTP) News
Filter MTP News Items
MTP News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
MTP News Highlights
- For MTP, its 30 day story count is now at 5.
- Over the past 21 days, the trend for MTP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO, DRUG and GM are the most mentioned tickers in articles about MTP.
Latest MTP News From Around the Web
Below are the latest news stories about MIDATECH PHARMA PLC that investors may wish to consider to help them evaluate MTP as an investment opportunity.
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of EquityBiodexa Pharmaceuticals PLC (AIM:BDRX; Nasdaq:BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has today issued to various investors 18,636,190 new ordinary shares of £0.02 each in the Company ("New Ordinary Shares"), pursuant to the exercise notices in respect of 1,738,136 A Warrants and 1,989,102 B Warrants received yesterday. |
Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal DiseaseMidatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs. |
Midatech Pharma PLC Announces Results of General MeetingMidatech Pharma PLC (AIM:MTPH)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed. |
Midatech Pharma PLC Announces Further re: Notice of General MeetingFurther to the announcement made on 8 March 2023 providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "Notice") and form of proxy (the "Form of Proxy"), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy: |
Midatech Pharma PLC Announces Posting of Circular and Notice of General MeetingMidatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces, further to the Company's announcements of 9 February and 15 February 2023, that a circular (the "Circular") and formal Notice of General Meeting was posted to shareholders yesterday and will be made available on the Company's website at: www.midatechpharma.com/investors/shareholder-information. |
Midatech Pharma PLC Announces Closing of $6.0m Private Placement & Broker ChangeMidatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces the closing of the Private Placement of 10,344,822 Units initially at an issue price of US$0.58 per Unit (further details of which were set out in the announcement of 9 February 2023). |
Midatech Pharma PLC Announces Private Placement Raising US $6.0 millionMidatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces that it has entered into definitive binding agreements with certain institutional US investors ("Placees") to raise aggregate gross proceeds of approximately US$6.0 million (approximately £5.0 million) (the "Private Placement") by the issue and allotment of, in aggregate, 10,344,822 Units |
Midatech Pharma PLC Announces Receipt of NASDAQ NoticeMidatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 31 January 2023, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital |
Midatech Pharma PLC Announces Result of General MeetingMidatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that at its General Meeting held at 10.00 a.m. today all ordinary resolutions were carried, but all other resolutions were not passed by shareholders, as set out in the table below. |
Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 StudyMidatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following completion of one month of treatment with MTX-110 in the first patient, its Phase I study of MTX-110 in recurrent glioblastoma ("rGB") (NCT 05324501) will continue with a planned dose escalation following a positive recommendation from the study's Data Safety Monitoring |